Clinical trials: Disorder of Circulatory System
Ischemic Stroke
Assess the Penumbra System in the Treatment of Acute Stroke
The purpose of this trial is to assess the safety and effectiveness of the Penumbra System as an adjunctive treatment to intravenous (IV) recombinant human tissue plasminogen activator (rtPA)in patients with acute ischemic stroke…
- Trial name
- THERAPY (NCT01429350)
- Testing
- intravenous (IV) recombinant human tissue plasminogen activator (rtPA), Penumbra System
- Where
- 4 sites in United States
- Volunteers
- 108 people
- Sponsor
- Penumbra Inc.
Cardiovascular Diseases
A Multicenter Observational Registry to Evaluate Safety and Performance of Vivo ISAR (SECURE Global Registry)
The objective of this post marketing observational registry is to evaluate clinical outcomes (safety and performance) in an all-comers population with coronary artery disease (CAD) treated with the Polymer Free Sirolimus Eluting…
- Trial name
- NCT06412250
- Where
- 32 sites in India, Italy and 2 more
- Volunteers
- 2,000 people
- Sponsor
- Translumina Therapeutics Pvt Ltd.
Coronary Artery Stenosis
Coronary Laser Atherectomy System for Treatment of Coronary Artery Stenosis (SHINE)
This prospective, multi-center clinical trial evaluates the safety and efficacy of the Coronary Laser Atherectomy System for the pretreatment of coronary artery stenosis.
- Trial name
- SHINE (NCT07697638)
- Testing
- Coronary Laser Atherectomy System, CVX300 Laser System
- Volunteers
- 218 people
- Sponsor
- Shanghai MicroPort Rhythm MedTech Co., Ltd.
Fabry Disease
A Study of Two Fabrazyme (Agalsidase Beta) Dosing Regimens in Treatment-naïve, Male Pediatric Patients Without Severe Symptoms
The purpose of this study was to determine whether 2 alternative dosing regimens of Fabrazyme (Agalsidase beta) (1.0 mg/kg every 4 weeks or 0.5 mg/kg every 2 weeks) were effective in treatment-naïve pediatric participants without…
- Trial name
- FIELD (NCT00701415)
- Testing
- Agalsidase beta
- Where
- 12 sites in United States, Argentina and 7 more
- Volunteers
- 31 people
- Sponsor
- Genzyme, a Sanofi Company
Multiple Myeloma
Phase I Clinical Study of CBG002 CAR-T Cell in Treatment of Relapsed/refractory Multiple Myeloma
This is a single arm study to evaluate the efficacy and safety of BCMA-targeted CAR-T cells therapy for patients with relapsed/refractory Multiple Myeloma.
- Trial name
- NCT06705725
- Testing
- CBG002 CAR-T Cell Suspension
- Volunteers
- 38 people
- Sponsor
- Carbiogene Therapeutics Co. Ltd.
Stroke, Ischemic
SYNCHRONISE: LVO Triage Timing and Outcome Study
The objective of this study is to evaluate the impact of Viz LVO in hospital systems with non-interventional and interventional (spoke and hub) stroke centers on the timing and outcomes of patients with suspected acute ischemic…
- Trial name
- NCT04608617
- Testing
- Viz LVO (De Novo Number DEN170073), Baseline Effectiveness Cohort
- Where
- 3 sites in United States
- Volunteers
- 600 people
- Sponsor
- Viz.ai, Inc.
Stroke, Acute
Detection of hEad Pulse for Ischemic StrOke Verification Study
Prehospital providers encounter patients with suspected stroke frequently. Prehospital providers need tools to help triage large vessel stroke patients to comprehensive stroke centers.
- Trial name
- EPISODE_VS (NCT05602740)
- Testing
- Harmony
- Where
- United States
- Volunteers
- 500 people
- Sponsor
- MindRhythm, Inc.
Reconstructive Surgical Procedures, Plastic Surgery
Leica Microsystems Sponsored Study to Collect and Confirm Clinical Data on the Performance of the GLOW800 Device When Used in Accordance With Its Intended Use.
This post-market clinical follow-up (PMCF) study aims to confirm the safety and performance of the GLOW800 surgical microscope accessory when used in conjunction with the ARveo8x surgical microscope.
- Conditions
- Reconstructive Surgical Procedures, Plastic Surgery, Vascular Surgical Procedure, Cerebrovascular Disorder
- Trial name
- IMED-GLOW800 (NCT07164040)
- Testing
- The GLOW800, a non-contact, non-invasive device, allows the surgical microscope ARveo 8 and ARveo 8X to produce excitation light and resolve fluorescence emission from the fluorescent agent ICG
- Where
- 3 sites in Portugal, Spain and 1 more
- Volunteers
- 31 people
- Sponsor
- Leica Microsystems (Schweiz) AG
Diabetic Foot Ulcer
Study of the Efficacy of PedyPhar® Ointment on the Diabetic Foot Ulcers
Clinical Trial Phase III-b Study Sponsor: European Egyptian Pharmaceutical Industries Sample Size: 120 patients (60 per arm) Study Population: Patients with Diabetic foot ulcer of any stage after proper surgical treatment - if…
- Trial name
- PED111 (NCT01531517)
- Testing
- Royal Jelly and Panthenol (PedyPhar® Ointment), Panthenol Ointment
- Where
- 2 sites in Egypt
- Volunteers
- 47 people
- Sponsor
- European Egyptian Pharmaceutical Industries
Coronary Artery Disease, Myocardial Infarction
Disrupt CAD III With the Shockwave Coronary IVL System
The study design is a prospective, multicenter, single-arm, global IDE study to evaluate the safety and effectiveness of the Shockwave Medical Coronary Intravascular Lithotripsy (IVL) System in de novo, calcified, stenotic…
- Trial name
- NCT03595176
- Testing
- Lithotripsy
- Where
- 48 sites in United States, France and 2 more
- Volunteers
- 431 people
- Sponsor
- Shockwave Medical, Inc.
Myocardial Infarction, Heart Failure, Congestive
Safety and Effects of Implanted (Autologous) Skeletal Myoblasts (MyoCell) Using an Injection Catheter = SEISMIC Trial
To assess the efficacy and safety of MyoCell therapy on myocardial function in congestive heart failure patients, post-myocardial infarction
- Trial name
- NCT00375817
- Testing
- Myoblasts injection with MyoCath catheter
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Bioheart, Inc.
Atrial Fibrillation
Foresight Intracardiac Echocardiography (ICE) System
This study will evaluate the efficacy of 2D forward-looking and 3D Intracardiac Echocardiography (ICE) to guide septal punctures during Atrial Fibrillation ablation procedures.
- Trial name
- NCT02514876
- Testing
- Foresight ICE System
- Where
- Canada
- Volunteers
- 10 people
- Sponsor
- Conavi
Diabetic Foot Ulcer
Nonhealing Diabetic Foot Ulcers Treated With Standard of Care (SOC) Alone or Standard of Care and Amnion-Intermediate-Chorion (AIC)
The purpose of this study is to determine how well our dHPT (Dehydrated Human Placental Tissue) Product and Standard of Care work when compared to Standard of Care alone in achieving complete closure of diabetic foot.
- Trial name
- ELITE (NCT07014176)
- Testing
- Amnion-Intermediate-Chorion, Standard of Care (SOC)
- Where
- 8 sites in United States
- Volunteers
- 84 people
- Sponsor
- Cellution Biologics
Multiple Myeloma
A Study of Venetoclax and ABBV-838 Combination Therapy With Dexamethasone in Participants With Multiple Myeloma Whose Cancer Has Come Back or Had No Response to Recent Cancer Treatment
This is an open-label, multicenter clinical trial designed to evaluate the safety and potential efficacy of venetoclax and ABBV-838 combination therapy with dexamethasone in participants with relapsed or refractory multiple…
- Trial name
- NCT02951117
- Testing
- Venetoclax, ABBV-838, Dexamethasone
- Where
- 3 sites in Australia
- Sponsor
- AbbVie
Diabetes Mellitus, Type 2
Evaluating Comparative Effectiveness of Empagliflozin in Type 2 Diabetes Population With and Without Chronic Kidney Disease
The primary purpose of this research study is to determine the cardiovascular and renal effectiveness and safety of empagliflozin compared to dipeptidyl peptidase-4 inhibitors (DPP4i) in patients with Type 2 Diabetes Mellitus…
- Trial name
- NCT05465317
- Testing
- Empagliflozin, Dipeptidyl Peptidate-4 inhibitors
- Where
- United States
- Volunteers
- 62,197 people
- Sponsor
- Boehringer Ingelheim
Multiple Myeloma
Safety and Efficacy Study of GCS-100LE in the Treatment of Multiple Myeloma
A Phase 1, open-label, dose escalation, multi-center study in patients who have been diagnosed with multiple myeloma and who have relapsed or have refractory/relapsed disease after treatment with at least 2 prior therapies.
- Trial name
- NCT00609817
- Testing
- GCS-100, Bortezomib/Dexamethasone
- Where
- 3 sites in United States
- Volunteers
- 9 people
- Sponsor
- La Jolla Pharmaceutical Company
Heart Failure
Feasibility Trial of the DC Devices Interatrial Septal Device (IASD) System
The purpose of this study is to evaluate the safety and potential benefits of the interatrial septal defect (IASD) System in patients with heart failure with preserved ejection fraction.
- Trial name
- NCT01570517
- Testing
- IASD System
- Where
- 3 sites in Australia, Czechia and 1 more
- Volunteers
- 11 people
- Sponsor
- Corvia Medical
Hypotension, Orthostatic
A Phase IV Study in Subjects With Neurogenic Orthostatic Hypotension
We are seeking male and female patients to voluntarily take part in a clinical research study. Patients must be aged 18 or older and diagnosed with symptomatic orthostatic hypotension (low blood pressure while in the upright…
- Trial name
- NCT00046163
- Testing
- midodrine hydrochloride (ProAmatine®)
- Where
- 3 sites in United States
- Volunteers
- 150 people
- Sponsor
- Shire
Turner Syndrome
The Efficacy and Safety of Inpegsomatropin Injection in Children With Turner Syndrome (TS) and Short Stature
This is a multicenter, randomized, open-label, positive-controlled phase III confirmatory clinical study. A total of 84 children with short stature due to Turner Syndrome (TS) are planned to be enrolled.
- Trial name
- NCT07614152
- Testing
- Inpegsomatropin-Injection, Givopegsomatropin Solution Injection
- Where
- 51 sites in China
- Volunteers
- 84 people
- Sponsor
- Xiamen Amoytop Biotech Co., Ltd.
Multiple Myeloma
Study of Tecemotide (L-BLP25) in Subjects With Slowly Progressive Multiple Myeloma With no Symptoms and Who Have Had no Chemotherapy
Tecemotide (L-BLP25) is believed to induce a Mucinous glycoprotein 1 (MUC1)-specific T-cell response after vaccination. The primary purpose of this study is to ascertain whether vaccination with tecemotide (L-BLP25) induces a…
- Trial name
- NCT01094548
- Testing
- Tecemotide (L-BLP25), Single low dose cyclophosphamide, Multiple low dose cyclophosphamide
- Where
- Germany
- Volunteers
- 34 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
The first 5,000 results can be paged through. Add a filter or change the sort order to reach the rest.